Items Tagged ‘Florida News Release’
December 12th, 2014 · Leave a Comment
By Kevin Punsky
JACKSONVILLE, Fla. — Mayo Clinic has appointed Christina Zorn, J.D., as chief administrative officer of its campus in Jacksonville, Fla., and vice chair of Administration, Mayo Clinic.
She will serve as administrative partner to Gianrico Farrugia, M.D., incoming vice president of Mayo Clinic and chief executive officer of the Jacksonville campus, as previously announced. Zorn assumes her new role on Jan. 1.
“Christina Zorn has significant experience at Mayo Clinic as well as excellent insight into the strengths of Mayo Clinic’s Florida staff and the unique challenges of the local and regional market,” says Dr. Farrugia. “I look forward to working with Christina as we continue the excellent efforts underway in delivering outstanding care to our patients, advancing research and educating the next generation of providers in Florida and throughout the Southeast.”
Zorn has been with Mayo Clinic since 2002. She began her career at Mayo Clinic as a legal counsel and now serves as the chair of the Florida division of the Legal Department. In addition, Zorn has served as an administrator for the Department of Ophthalmology in Florida and for several key initiatives.
She succeeds Robert Brigham, who has served as chief administrative officer in Florida since 2005. Brigham will retire from Mayo Clinic at the end of 2014. Zorn will work closely with Brigham to ensure a smooth leadership transition.
MEDIA CONTACT: Kevin Punsky, Mayo Clinic Public Affairs, 904-953-0746,email@example.com Read the rest of this entry »
December 8th, 2014 · Leave a Comment
By Paul Scotti
JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker — the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy — appears irrelevant when trastuzumab is used.
Tags: 2014 San Antonio Breast Cancer Symposium, Breast Cancer, Edith Perez, Florida News Release, HER2+ breast cancer, M.D., Mayo Clinic Cancer Center, Mayo Clinic in Florida, News Release, trastuzumab Herceptin, triple negative breast cancer, cancer
November 14th, 2014 · Leave a Comment
JACKSONVILLE, Fla. — The Mayo Clinic Board of Trustees welcomed Mary Sue Coleman, Ph.D., as a new public member at its quarterly meeting today.
Dr. Coleman is president emeritus of the University of Michigan, (U-M) an institution she led for 12 years before retiring in July 2014. Time magazine named her one of the nation’s “10 best college presidents,” and the American Council on Education honored her with its Lifetime Achievement Award. She previously was president of the University of Iowa.
As University of Michigan president, Dr. Coleman unveiled several major initiatives designed to impact on future generations of students, the intellectual life of the campus, and society at large. The initiatives focused on the interdisciplinary richness of the U-M, student residential life, the economic vitality of the state and nation, global engagement and the value of innovation and creativity. President Obama chose Dr. Coleman to help launch the Advanced Manufacturing Partnership, a national effort bringing together industry, universities and the federal government.
Click here for a bio of Dr. Mary Sue Coleman.
MEDIA CONTACT: Karl Oestreich, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org.
November 10th, 2014 · Leave a Comment
By Kevin Punsky
JACKSONVILLE, Fla. — Researchers at Mayo Clinic’s campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore.
In an online issue of Cancer Discovery, the scientists described the molecular steps necessary for acinar cells in the pancreas — the cells that release digestive enzymes — to become precancerous lesions. Some of these lesions can then morph into cancer.
“Pancreatic cancer develops from these lesions, so if we understand how these lesions come about, we may be able to stop the cancer train altogether,” says the study’s lead investigator, Peter Storz, Ph.D., a cancer biologist.
he need for new treatment and prevention strategies is pressing, Dr. Storz says. Pancreatic cancer is one of the most aggressive human cancers — symptoms do not occur until the cancer is well advanced. One-year survival after diagnosis is only 20 percent. It is the fourth leading cause of cancer death in this country.
The scientists studied pancreatic cells with Kras genetic mutations. Kras produces a protein that regulates cell division, and the gene is often mutated in many cancers. More than 95 percent of pancreatic cancer cases have a Kras mutation.
The researchers detailed the steps that led acinar cells with Kras mutations to transform into duct-like cells with stem cell-like properties. Stem cells, which can divide at will, are also often implicated in cancer.
November 9th, 2014 · Leave a Comment
By Paul Scotti
JACKSONVILLE, Fla., Nov. 9, 2014 — All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.
Now, at the American Association for the Study of Liver Diseases (The Liver Meeting® 2014) in Boston, researchers at Mayo Clinic report that use of two new oral medications post-transplant is safe and beneficial, and requires only 12 weeks of treatment.
“This is the first study to examine the use of these two new drugs — simeprevir and sofosbuvir — in liver transplant recipients, and, based on this large study, we find it to be a better option than current treatment,” says the study’s lead researcher, Surakit Pungpapong, M.D., a transplant hepatologist and an associate professor of medicine at Mayo Clinic in Florida.
Journalists: Soundbites with Dr. Pungpapong are available in the downloads.
October 23rd, 2014 · Leave a Comment
By Kevin Punsky
JACKSONVILLE, Fla. — The National Institute of Neurological Disorders and Stroke (NINDS) and the U.S. Department of Defense have awarded researchers at Mayo Clinic’s campus in Jacksonville approximately $6 million in two grants to further their studies aimed at improving the diagnosis and treatment of patients suffering from either amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease and frontotemporal dementia (FTD).
NINDS has awarded Leonard Petrucelli, Ph.D., chair of the Department of Neuroscience, and his colleagues Kevin Boylan, M.D., Rosa Rademakers, Ph.D., and Dennis Dickson, M.D., a five-year P01 grant (P01 NS084974-1) to combine their expertise in neurology, genetics, neuropathology and cell biology. Given that no biomarker or blood test currently exists for clinicians to definitely diagnose ALS or FTD, the funding will allow researchers to improve understanding of C9ORF72-related neurodegeneration, identify potential biomarkers and therapeutic targets, and develop a biological fluid and tissue resource to aid future drug discovery.
October 21st, 2014 · Leave a Comment
By Paul Scotti
Years After Treatment for HER2-Positive Early Stage Breast Cancer Trastuzumab Shows Life-Altering Benefit
JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.
They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone.
These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. Read the rest of this entry »
September 29th, 2014 · Leave a Comment
By Paul Scotti
JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.
September 19th, 2014 · Leave a Comment
By Kevin Punsky
JACKSONVILLE, Fla. — Researchers at Jacksonville’s campus of Mayo Clinic have discovered a defect in a key cell-signaling pathway they say contributes to both overproduction of toxic protein in the brains of Alzheimer’s disease patients as well as loss of communication between neurons — both significant contributors to this type of dementia.
Their study, in the online issue of Neuron, offers the potential that targeting this specific defect with drugs “may rejuvenate or rescue this pathway,” says the study’s lead investigator, Guojun Bu, Ph.D., a neuroscientist at Mayo Clinic, Jacksonville, Fla.
“This defect is likely not the sole contributor to development of Alzheimer’s disease, but our findings suggest it is very important, and could be therapeutically targeted to possibly prevent Alzheimer’s or treat early disease,” he says.
September 12th, 2014 · Leave a Comment
By Paul Scotti
JACKSONVILLE, Fla., Sept. 12, 2014 — The liver transplant team at Mayo Clinic in Florida has found, based on 12 years of experience, that more than half of patients receiving a new liver can be “fast-tracked” to return to a surgical ward room following their transplant, bypassing a one- or two-day stay in the Intensive Care Unit (ICU).
In the September issue of the American Journal of Transplantation, the physicians and researchers have turned their knowledge of who can be safely fast-tracked into a scoring system that other transplant centers can also use — thus sparing patients potentially overly aggressive treatment and saving substantial health care dollars.